Metrika
This article was originally published in The Gray Sheet
Executive Summary
Firm is seeking an exclusive marketing and distribution partner for its DRx quantitative hCG patient monitor, for which FDA market go-ahead was announced Oct. 6. The single-use device measures levels of human chorionic gonadotropin (hCG) hormone in whole blood and is designed for use as an aid in monitoring pregnancy status. The test can be performed in a physician's office and provides results in less than ten minutes, according to the company